Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
BPC 157 is not FDA approved to treat ulcerative colitis, Crohn's disease, IBS, or any other medical condition in humans
At a standard 500 mcg per-compound dose, this lands on 10 units (0.1 mL) on a U-100 insulin syringe
Y.et al (2007)
A 2025 meta-analysis examining over 142,000 participants found that tirzepatide produced significantly greater weight loss than semaglutide, an average of 4.23% more body weight lost
Yes, when monitored clinically, IGF-1 LR3 shows predictable receptor activity and a well-tolerated safety profile in preclinical human data, provided glucose and hormone levels are regularly evaluated
US$ 26.60
US$ 26.01
US$ 28.88
